| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 57 | 2025 | 589 | 15.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2025 | 409 | 8.500 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 13 | 2021 | 37 | 5.780 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2024 | 330 | 4.230 |
Why?
|
| Immunoconjugates | 8 | 2024 | 21 | 3.640 |
Why?
|
| Uterine Cervical Neoplasms | 18 | 2023 | 297 | 3.550 |
Why?
|
| Fallopian Tube Neoplasms | 10 | 2020 | 52 | 3.350 |
Why?
|
| Indazoles | 6 | 2020 | 18 | 3.190 |
Why?
|
| Piperidines | 5 | 2020 | 48 | 2.960 |
Why?
|
| Peritoneal Neoplasms | 8 | 2020 | 79 | 2.910 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2024 | 144 | 2.910 |
Why?
|
| Phthalazines | 7 | 2021 | 22 | 2.900 |
Why?
|
| Female | 101 | 2025 | 15156 | 2.700 |
Why?
|
| Piperazines | 6 | 2021 | 47 | 2.680 |
Why?
|
| Aged | 60 | 2025 | 5400 | 2.480 |
Why?
|
| Middle Aged | 66 | 2025 | 7138 | 2.450 |
Why?
|
| Genital Neoplasms, Female | 7 | 2020 | 67 | 2.410 |
Why?
|
| Clinical Trials as Topic | 9 | 2024 | 214 | 2.320 |
Why?
|
| Antineoplastic Agents | 12 | 2023 | 679 | 2.200 |
Why?
|
| Humans | 109 | 2025 | 28097 | 2.160 |
Why?
|
| Maytansine | 5 | 2024 | 6 | 2.100 |
Why?
|
| Endometrial Neoplasms | 11 | 2019 | 189 | 2.030 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2019 | 109 | 2.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 9 | 2018 | 72 | 1.970 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 2021 | 1.970 |
Why?
|
| Bevacizumab | 13 | 2023 | 103 | 1.880 |
Why?
|
| Folate Receptor 1 | 5 | 2024 | 13 | 1.870 |
Why?
|
| Carboplatin | 14 | 2021 | 111 | 1.830 |
Why?
|
| Carcinoma, Endometrioid | 7 | 2023 | 41 | 1.770 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 44 | 1.680 |
Why?
|
| Adult | 48 | 2025 | 7740 | 1.680 |
Why?
|
| Paclitaxel | 14 | 2021 | 190 | 1.560 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 405 | 1.490 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 42 | 1.410 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 21 | 1.320 |
Why?
|
| BRCA2 Protein | 5 | 2021 | 19 | 1.270 |
Why?
|
| BRCA1 Protein | 5 | 2021 | 24 | 1.260 |
Why?
|
| Neoplasms | 6 | 2022 | 809 | 1.210 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2019 | 233 | 1.170 |
Why?
|
| Retrospective Studies | 30 | 2025 | 2546 | 1.160 |
Why?
|
| Precision Medicine | 3 | 2018 | 76 | 1.070 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2017 | 32 | 1.070 |
Why?
|
| Patient Selection | 3 | 2017 | 148 | 1.070 |
Why?
|
| Patient Participation | 2 | 2025 | 56 | 1.020 |
Why?
|
| Mutation | 7 | 2021 | 847 | 0.990 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 135 | 0.940 |
Why?
|
| Neoplasm Staging | 20 | 2022 | 478 | 0.940 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2023 | 167 | 0.930 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 17 | 0.900 |
Why?
|
| Cisplatin | 8 | 2019 | 179 | 0.890 |
Why?
|
| Disease-Free Survival | 10 | 2020 | 237 | 0.850 |
Why?
|
| Treatment Outcome | 17 | 2021 | 2379 | 0.800 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 6 | 0.790 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 607 | 0.780 |
Why?
|
| Subcutaneous Fat | 2 | 2021 | 17 | 0.750 |
Why?
|
| Intra-Abdominal Fat | 2 | 2021 | 21 | 0.750 |
Why?
|
| Angiopoietin-2 | 2 | 2019 | 10 | 0.750 |
Why?
|
| Platinum | 1 | 2021 | 18 | 0.750 |
Why?
|
| Angiopoietin-1 | 2 | 2019 | 8 | 0.750 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 37 | 0.750 |
Why?
|
| Cardiotoxicity | 2 | 2019 | 4 | 0.740 |
Why?
|
| Quality of Life | 2 | 2023 | 487 | 0.730 |
Why?
|
| Lymph Nodes | 7 | 2023 | 103 | 0.730 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 156 | 0.730 |
Why?
|
| Oligopeptides | 1 | 2021 | 97 | 0.710 |
Why?
|
| Pyrazoles | 5 | 2021 | 66 | 0.700 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2017 | 33 | 0.700 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2022 | 113 | 0.700 |
Why?
|
| Double-Blind Method | 6 | 2021 | 417 | 0.690 |
Why?
|
| Benzodiazepines | 1 | 2020 | 10 | 0.680 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 15 | 0.680 |
Why?
|
| Pyrroles | 1 | 2020 | 36 | 0.670 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2024 | 20 | 0.650 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 103 | 0.650 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2019 | 4 | 0.640 |
Why?
|
| Long QT Syndrome | 1 | 2019 | 13 | 0.620 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 58 | 0.620 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 77 | 0.610 |
Why?
|
| Tablets | 1 | 2018 | 6 | 0.590 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 149 | 0.580 |
Why?
|
| Dietary Fats | 1 | 2018 | 59 | 0.560 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2008 | 35 | 0.560 |
Why?
|
| Obesity | 4 | 2019 | 669 | 0.540 |
Why?
|
| Hyperinsulinism | 1 | 2017 | 16 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2021 | 474 | 0.540 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 250 | 0.520 |
Why?
|
| Prognosis | 8 | 2020 | 803 | 0.500 |
Why?
|
| Organoplatinum Compounds | 4 | 2021 | 24 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 385 | 0.450 |
Why?
|
| Young Adult | 8 | 2024 | 2733 | 0.450 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 16 | 0.450 |
Why?
|
| Quinolines | 1 | 2014 | 25 | 0.440 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2021 | 7 | 0.430 |
Why?
|
| Cohort Studies | 5 | 2019 | 887 | 0.410 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 459 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 163 | 0.400 |
Why?
|
| Pyrimidinones | 3 | 2021 | 16 | 0.400 |
Why?
|
| United States | 4 | 2025 | 2146 | 0.400 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 107 | 0.390 |
Why?
|
| Medical Oncology | 3 | 2020 | 94 | 0.380 |
Why?
|
| Uterine Neoplasms | 2 | 2014 | 71 | 0.370 |
Why?
|
| Age Factors | 6 | 2017 | 734 | 0.370 |
Why?
|
| Benzimidazoles | 3 | 2021 | 32 | 0.370 |
Why?
|
| Sulfonamides | 2 | 2024 | 73 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 73 | 0.350 |
Why?
|
| Peritoneum | 2 | 2023 | 8 | 0.340 |
Why?
|
| Salvage Therapy | 1 | 2010 | 34 | 0.340 |
Why?
|
| Lymph Node Excision | 6 | 2023 | 100 | 0.340 |
Why?
|
| Nausea | 3 | 2019 | 17 | 0.340 |
Why?
|
| Diarrhea | 3 | 2021 | 55 | 0.340 |
Why?
|
| Genes, BRCA2 | 2 | 2021 | 10 | 0.330 |
Why?
|
| Genes, BRCA1 | 2 | 2021 | 12 | 0.330 |
Why?
|
| Pyrazines | 2 | 2021 | 24 | 0.330 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 30 | 0.320 |
Why?
|
| Fatigue | 3 | 2019 | 64 | 0.320 |
Why?
|
| Survival Analysis | 4 | 2021 | 288 | 0.320 |
Why?
|
| Doxorubicin | 5 | 2019 | 77 | 0.320 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 224 | 0.310 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 31 | 0.310 |
Why?
|
| Neutropenia | 3 | 2018 | 41 | 0.310 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 125 | 0.310 |
Why?
|
| Thrombocytopenia | 3 | 2020 | 113 | 0.300 |
Why?
|
| Adolescent | 5 | 2019 | 3122 | 0.300 |
Why?
|
| Cervical Intraepithelial Neoplasia | 2 | 2007 | 82 | 0.290 |
Why?
|
| Survival Rate | 6 | 2017 | 430 | 0.280 |
Why?
|
| Vesicovaginal Fistula | 1 | 2007 | 4 | 0.280 |
Why?
|
| Prospective Studies | 4 | 2021 | 1248 | 0.270 |
Why?
|
| Abdominal Fat | 2 | 2017 | 17 | 0.270 |
Why?
|
| Incidence | 2 | 2018 | 562 | 0.260 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 298 | 0.250 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 38 | 0.250 |
Why?
|
| Fallopian Tubes | 2 | 2023 | 15 | 0.240 |
Why?
|
| Taxoids | 3 | 2017 | 37 | 0.240 |
Why?
|
| Electrocardiography | 2 | 2019 | 394 | 0.240 |
Why?
|
| Gynecology | 2 | 2016 | 58 | 0.230 |
Why?
|
| Europe | 1 | 2025 | 98 | 0.230 |
Why?
|
| Risk Assessment | 2 | 2018 | 612 | 0.220 |
Why?
|
| Abdominal Pain | 1 | 2023 | 35 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 194 | 0.210 |
Why?
|
| Adiposity | 2 | 2021 | 94 | 0.210 |
Why?
|
| Area Under Curve | 3 | 2018 | 95 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 64 | 0.200 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 300 | 0.200 |
Why?
|
| Homologous Recombination | 1 | 2022 | 10 | 0.190 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 35 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 39 | 0.180 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 31 | 0.180 |
Why?
|
| Time Factors | 2 | 2019 | 1592 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 11 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 47 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 27 | 0.180 |
Why?
|
| DNA Damage | 2 | 2019 | 151 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 18 | 0.170 |
Why?
|
| Dipeptidases | 1 | 2020 | 5 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2014 | 163 | 0.170 |
Why?
|
| Platinum Compounds | 2 | 2017 | 14 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 112 | 0.170 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2019 | 4 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 5 | 0.170 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 6 | 0.160 |
Why?
|
| Injections, Intraperitoneal | 1 | 2019 | 35 | 0.160 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 65 | 0.160 |
Why?
|
| Genomics | 2 | 2022 | 123 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2022 | 251 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2019 | 110 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2020 | 253 | 0.160 |
Why?
|
| Canada | 1 | 2019 | 60 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 55 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 57 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2019 | 75 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 155 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 186 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2018 | 9 | 0.150 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Epistaxis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Food-Drug Interactions | 1 | 2018 | 3 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2025 | 21 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 2018 | 4 | 0.150 |
Why?
|
| Proteinuria | 1 | 2018 | 14 | 0.150 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 5 | 0.150 |
Why?
|
| Vomiting | 1 | 2018 | 14 | 0.150 |
Why?
|
| Headache | 1 | 2018 | 34 | 0.140 |
Why?
|
| Intestinal Perforation | 1 | 2018 | 15 | 0.140 |
Why?
|
| Prodrugs | 1 | 2018 | 30 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2019 | 183 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2018 | 36 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2017 | 433 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 43 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 2017 | 19 | 0.140 |
Why?
|
| Fasting | 1 | 2018 | 82 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.140 |
Why?
|
| Ascitic Fluid | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 62 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2018 | 125 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Age of Onset | 1 | 2017 | 70 | 0.130 |
Why?
|
| Glycolysis | 1 | 2017 | 85 | 0.130 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 60 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2014 | 611 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2017 | 123 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 234 | 0.130 |
Why?
|
| Life Style | 1 | 2017 | 89 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2016 | 22 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 164 | 0.130 |
Why?
|
| Health Care Reform | 1 | 2016 | 13 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 55 | 0.130 |
Why?
|
| Brachytherapy | 1 | 2016 | 51 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 265 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2016 | 53 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 94 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 10 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 32 | 0.120 |
Why?
|
| Carcinoma | 2 | 2014 | 74 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 58 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 547 | 0.120 |
Why?
|
| Hypertension | 1 | 2018 | 308 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2015 | 25 | 0.120 |
Why?
|
| Diet | 1 | 2017 | 232 | 0.120 |
Why?
|
| Cyclophosphamide | 2 | 2019 | 41 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2016 | 399 | 0.110 |
Why?
|
| Aorta, Abdominal | 1 | 2014 | 15 | 0.110 |
Why?
|
| Sarcoma | 1 | 2014 | 29 | 0.110 |
Why?
|
| Action Potentials | 1 | 2014 | 196 | 0.110 |
Why?
|
| Recurrence | 2 | 2013 | 322 | 0.100 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 29 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2015 | 206 | 0.100 |
Why?
|
| Benzopyrans | 1 | 2013 | 22 | 0.100 |
Why?
|
| Biomarkers | 1 | 2016 | 765 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 21 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 2014 | 270 | 0.100 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 101 | 0.100 |
Why?
|
| Cetuximab | 1 | 2012 | 21 | 0.100 |
Why?
|
| Animals | 4 | 2019 | 10423 | 0.100 |
Why?
|
| Infusions, Parenteral | 3 | 2017 | 37 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 59 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 379 | 0.100 |
Why?
|
| Inflammation | 1 | 2016 | 636 | 0.090 |
Why?
|
| Pelvis | 2 | 2023 | 38 | 0.090 |
Why?
|
| Laparoscopy | 3 | 2014 | 146 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1013 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 330 | 0.090 |
Why?
|
| Colposcopy | 2 | 2007 | 61 | 0.090 |
Why?
|
| Male | 5 | 2020 | 13491 | 0.090 |
Why?
|
| Oklahoma | 1 | 2014 | 1007 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 1319 | 0.080 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 59 | 0.080 |
Why?
|
| Hysterectomy | 2 | 2013 | 85 | 0.080 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 31 | 0.080 |
Why?
|
| Weight Loss | 1 | 2009 | 81 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2007 | 722 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 30 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 269 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 51 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 83 | 0.070 |
Why?
|
| Bridged-Ring Compounds | 1 | 2007 | 18 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2019 | 331 | 0.070 |
Why?
|
| Conization | 1 | 2007 | 11 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 44 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 162 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 202 | 0.070 |
Why?
|
| Comorbidity | 1 | 2008 | 258 | 0.070 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 12 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 2007 | 65 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 226 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 474 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 521 | 0.060 |
Why?
|
| Prevalence | 1 | 2007 | 497 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 143 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 104 | 0.060 |
Why?
|
| Oximes | 1 | 2024 | 8 | 0.060 |
Why?
|
| Laser Coagulation | 1 | 2003 | 13 | 0.050 |
Why?
|
| Dasatinib | 1 | 2023 | 18 | 0.050 |
Why?
|
| Endometrium | 1 | 2023 | 39 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2022 | 54 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 81 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 75 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 124 | 0.050 |
Why?
|
| Forecasting | 1 | 2022 | 76 | 0.050 |
Why?
|
| Placebos | 1 | 2021 | 48 | 0.050 |
Why?
|
| Enterocolitis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 50 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 68 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2022 | 68 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 102 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2020 | 6 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 236 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 19 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 7 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 38 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 41 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 35 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 4654 | 0.040 |
Why?
|
| Length of Stay | 2 | 2014 | 229 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 208 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 430 | 0.040 |
Why?
|
| Epothilones | 1 | 2018 | 5 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2018 | 7 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 13 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 125 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 29 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2018 | 24 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 104 | 0.040 |
Why?
|
| Sirolimus | 1 | 2018 | 76 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 2017 | 19 | 0.030 |
Why?
|
| Bortezomib | 1 | 2017 | 22 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 126 | 0.030 |
Why?
|
| Abdomen | 1 | 2017 | 41 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 144 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 806 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 161 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 235 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 463 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 453 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 193 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 178 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2015 | 12 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 15 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 407 | 0.030 |
Why?
|
| Honduras | 1 | 2014 | 2 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 681 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 86 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 50 | 0.030 |
Why?
|
| Developing Countries | 1 | 2014 | 49 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 2014 | 51 | 0.030 |
Why?
|
| Apoptosis | 1 | 2017 | 775 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 105 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 113 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 60 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 190 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2014 | 239 | 0.020 |
Why?
|
| Omentum | 1 | 2005 | 4 | 0.020 |
Why?
|
| Laparotomy | 1 | 2005 | 29 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 53 | 0.010 |
Why?
|